Company intelligence / Profile preview

Carcinotech

Roslin, Scotland, United Kingdomcarcinotech.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Carcinotech has developed and commercialized the Carcino3D™ platform, enabling rapid production of patient-derived 3D-bioprinted tumors for use in drug discovery, preclinical testing, and personalized medicine. The technology is used by pharmaceutical companies to accelerate oncology drug development with more physiologically relevant models. No clinical trial results are reported as the company is a service provider rather than a therapeutic developer.

Therapeutic areas: Oncology
Modalities: 3D-bioprinted tumor modelsCell-based assay systems
Industry: Non-Drug Biotech

Partnerships

Collaborations with pharmaceutical companies, biotech firms, CROs

Beyond the preview

Go deeper on Carcinotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Carcinotech.

Explore the full profile